


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A method of treating ocular hypertension or glaucoma which comprises administering to a mammal having ocular hypertension or glaucoma a therapeutically effective amount of a compound represented by formula I:




wherein the wavy segment represents an α or β bond, a dashed line represents the presence or absence of a bond, R is selected from the group consisting of CO₂R⁴, CONR⁴₂, CH₂OR⁴, CONR⁴SO₂R⁴, and P(O)(OR⁴);

wherein R⁴ is selected from the group consisting of H, phenyl and lower alkyl having from one to six carbon atoms and n is 0 or an integer of from 1 to 4, R¹ and R² are independently selected from the group consisting of hydrogen, hydroxyl, a lower alkyloxy radical having up to six carbon atoms, or a lower acyloxy radical having up to six carbon atoms, R³ is selected from the group consisting of hydrogen, a lower alkyl radical having up to six carbon atoms and a lower acyl radical having up to six carbon atoms, W is = O, Y is a covalent bond or is selected from the group consisting of CH₂, O, S and N and Z is a ~~alkyl or~~


cycloalkyl radical including from three to ten carbon atoms or an aromatic radical including a hydrocarbyl aromatic radical having from six to ten carbon atoms or a heterocyclic aromatic radical selected from benzo[b]thiophen-3-yl and 3-chlorobenzo[b]thiophen-2-yl ~~having from four to ten carbon atoms and including a heterocyclic atom selected from the group consisting of nitrogen, oxygen and sulfur;~~ and pharmaceutically-acceptable salts and esters thereof.

2. (Original) The method of Claim 1 wherein said compound is represented by formula II:




wherein the hatched segment represents an α bond and the solid triangle represents a β bond.

3. (Original) The method of claim 2 wherein said compound is represented by formula III




4. (Cancelled)
5. (Original) The method of claim 4 wherein U is S.
6. (Original) The method of claim 4 wherein R is CO₂R⁴.
7. (Original) The method of claim 6 wherein R is H or methyl.
8. (Original) The method of claim 4 wherein Z is phenyl.
9. (Original) The method of claim 8 wherein R is CO²R₄.
10. (Original) The method of claim 9 wherein R⁴ is H.
11. (Original) The method of claim 4 wherein Z is chlorobenzothienyl.
12. (Original) The method of claim 11 wherein R is CO²R₄.
13. (Original) The method of claim 12 wherein R⁴ is H.
14. (Original) An ophthalmic solution comprising a therapeutically effective amount of a compound of formula I, as defined in Claim 1, or a pharmaceutically acceptable salt thereof, in admixture with a non-toxic, ophthalmically acceptable liquid vehicle, packaged in a container suitable for metered application.
15. (Original) The ophthalmic solution of Claim 14 wherein said compound is a compound of Formula III



16. (Original) A pharmaceutical product, comprising a container adapted to dispense the contents of said container in metered form; and an ophthalmic solution in said container comprising a compound of formula I as defined in Claim 1, or a pharmaceutically acceptable salt thereof, in admixture with a non-toxic, ophthalmically acceptable liquid vehicle.

17. (Original) The product of claim 16 wherein said compound is compound of Formula III




18. (Original) The product of claim 17 wherein Z is phenyl.

19. (Original) The product of claim 18 wherein R is CO₂R⁴ wherein R⁴ is H or methyl.


20. (Original) The product of claim 19 wherein R⁴ is H.

21. (Currently Amended) The compound represented by formula I:




wherein the wavy segment represents an α or β bond, a dashed line represents the presence or absence of a bond, R is selected from the group consisting of CO_2R^4 , CONR^4_2 , CH_2OR^4 , $\text{CONR}^4\text{SO}_2\text{R}^4$, and $\text{P}(\text{O})(\text{OR}^4)_i$; wherein R^4 is selected from the group consisting of H, phenyl and lower alkyl having from one to six carbon atoms and n is 0 or an integer of from 1 to 4, R^1 and R^2 are independently selected from the group consisting of hydrogen, hydroxyl, a lower alkyloxy radical having up to six carbon atoms, or a lower acyloxy radical having up to six carbon atoms, R^3 is selected from the group consisting of hydrogen, a lower alkyl radical having up to six carbon atoms and a lower acyl radical having up to six carbon atoms, W is = O, Y is a covalent bond or is selected from the group consisting of CH_2 , O, S and N and Z is a ~~alkyl or cycloalkyl radical including from three to ten carbon atoms or an aromatic radical including a hydrocarbyl aromatic radical having from six to ten carbon atoms or a heterocyclic aromatic radical selected from benzo[b]thiophen-3-yl and 3-chlorobenzo[b]thiophen-2-yl having from four to ten carbon atoms and including a heterocyclic atom selected from the group consisting of nitrogen, oxygen and sulfur~~; and pharmaceutically-acceptable salts and esters thereof.

22. (Original) The compound of claim 1 wherein said compound is represented by formula II:



wherein the hatched segment represents an α bond and the solid triangle represents a β bond.

23. (Original) The method of claim 22 wherein said compound is represented by formula III



- 24. (Cancelled)
- 25. (Original) The method of claim 24 wherein U is S.
- 26. (Original) The method of claim 25 wherein R is CO_2R^4 .
- 27. (Original) The method of claim 26 wherein R is H or methyl.
- 28. (Original) The method of claim 24 wherein Z is phenyl.

29. (Original) The method of claim 28 wherein R is CO^2R_4 .
30. (Original) The method of claim 29 wherein R^4 is H.